Helen Thackray

(DR. Helen Thackray M.D.)

Currently holds positions in BioCryst Pharmaceuticals Inc and GlycoMimetics Inc

Positions
Position Company Period
Independent Director BioCryst Pharmaceuticals Inc Sept. 20, 2019 -
Senior Vice President - Clinical Development, Chief Medical Officer GlycoMimetics Inc Jan. 1, 2017 -
Vice President - Clinical Development, Chief Medical Officer GlycoMimetics Inc Jan. 1, 2012 - Jan. 1, 2017
Vice President - Clinical Development GlycoMimetics Inc Jan. 1, 2006 - Jan. 1, 2012
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2024-05-15 2024-05-14
B Purchase
30,000 +12.4%
5.86
USD 175,800
30,000 +12.4% 5.86 USD 175,800
2022-12-19 2022-12-15
PS Planned sale
3,125 -2.3%
10.89
USD
3,125 -2.3% 10.89 USD 34,031
2022-04-04 2022-04-01
PS Planned sale
7,600 -5.3%
16.20
USD
7,600 -5.3% 16.20 USD 123,120
2017-12-12 2017-12-08
S Sale
2,000 -1.3%
15.01
USD
2,000 -1.3% 15.01 USD 30,020
2017-09-18 2017-09-18
S Sale
2,000 -1.3%
13.00
USD
2,000 -1.3% 13.00 USD 26,000
2017-05-30 2017-05-25
S Sale
2,000 -1.3%
15.57
USD
2,000 -1.3% 15.57 USD 31,140
2017-05-22 2017-05-19
PS Planned sale
2,000 -1.3%
12.14
USD
2,000 -1.3% 12.14 USD 24,280
2016-10-04 2016-10-03
PS Planned sale
100 -0.1%
7.01
USD
100 -0.1% 7.01 USD 701
2016-10-04 2016-10-03
PS Planned sale
3,900 -2.4%
7.00
USD
3,900 -2.4% 7.00 USD 27,300
2016-07-21 2016-07-20
PS Planned sale
2,000 -1.2%
8.00
USD
2,000 -1.2% 8.00 USD 16,000
2016-07-06 2016-07-06
PS Planned sale
6,796 -4.0%
6.68
USD
6,796 -4.0% 6.68 USD 45,397
2016-07-06 2016-07-05
PS Planned sale
10,136 -5.6%
7.01
USD
10,136 -5.6% 7.01 USD 71,053
2016-07-06 2016-07-01
PS Planned sale
5,068 -2.7%
7.40
USD
5,068 -2.7% 7.40 USD 37,503